Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: Long-term follow-up

European Journal of Haematology

Volumn 56, Issue 1-2, 1996, Pages 78-81

  Kloke, O ^a   Niederle, N ^a,b   Opalka, B ^a   Hawig, I ^a   Seeber, S ^a   Becher, R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

Author keywords

CML; Cytogenetic response; IFN alpha; Prognosis

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029864653     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00299.x     Document Type: Article

References (14)

1. TALPAZ M, MCCREDIE KB, MAVLIGIT GM, GUTTERMAN JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983: 62: 689-692.
2. A in chronic myelogenous leukemia. New Engl J Med 1986: 314: 1065-1069.
3. NIEDERLE N, KLOKE O, OSIEKA R, et al. Interferon alpha-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 1987: 14: 29-35.
4. 1-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988: 69: 642-647.
5. OZER H, GEORGE SL, SCHIFFER CA, et al. Prolonged sucutaneous administration of recombinant 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583. Blood 1993: 82: 2975-2984.
6. TALPAZ M, KANTARJIAN HM, KURZROCK R, TRUJILLO JM, GUTTERMAN JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 1991: 114: 532-538.
7. KLOKE O, NIEDERLE N, QIU JY, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993: 83: 399-401.
8. KLOKE O, WANDL U, OPALKA B, et al. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol 1992: 48: 93-98.
9. KAPLAN EL, MEIER P. Non-parametric estimations from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
10. ANDERSON JR, CAIN KC, GELBER RD. Analysis of survival by tumor response. J Clin Oncol 1983: 1: 710-718.
11. MANTEL H, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959: 22: 719-748.
12. BUTZLER R, KLOKE O, EHNINGER G, et al. Follow-up of two patients with chronic myelogenous leukemia after withdrawal from interferon alpha treatment. Br J Haematol 1994: 87 (suppl. 1): 166.
13. THE ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994: 330: 820-825.
14. HEHLMANN R, HEIMPEL H, HASFORD J, et al. Randomized comparison of interferon- with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994: 84: 4064-4077.